Paradigm Biopharmaceuticals Ltd has released a press release.
PAR - 50% reduction in osteoarthritis pain maintained
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm OA Phase 2b Clinical Trial over 80% Recruited
- Paradigms phase 2 clinical data update
- Paradigm reports osteoarthritis pain reduced by 50%
- Half Year Accounts
- Quarterly Update and Appendix 4C
Later from Paradigm Biopharmaceuticals
- PAR achieves 100 per cent recruitment in Phase 2b OA Trial
- PAR achieves 60 per cent reduction in osteoarthritis pain
- Appendix 4E and 2018 Annual Report
- Phase2a RossRiver Virus Clinical Trial Recruitment Finalised
- PAR reports pain reduction in oa patients
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals